Overview

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1 study in healthy premenopausal females evaluating the effects of different dosing regimens of elagolix on ovarian activity, ovulation, and ovarian reserve and to assess the effect of elagolix on selected endocrine/hormone levels.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Neurocrine Biosciences